All Content Outsourced Pharma

  1. Bora Pharmaceuticals Capacity Update April 2025: Fill/Finish 4/25/2025

    Tara Lorenz, Sr. Director of Commercial Operations, speaks on our latest investments and expanded fill/finish capabilities and capacity for small molecules, biologics, and other sterile injectable products.

  2. Simtra Biopharma Solutions Capacity Update April 2025: Fill/Finish 4/25/2025

    With expertise in process optimization, analytics, and regulatory strategy, we help partners de-risk development, accelerate time to market, and ensure manufacturability from the outset.

  3. Mabion Capacity Update April 2025: Fill/Finish 4/25/2025

    Backed by years of dedication to customer-focused solutions, we’re proud to introduce our specialists to the global biopharma community and share insights that drive innovation forward.

  4. Resilience Capacity Update April 2025: Fill/Finish 4/25/2025

    In this update, you will hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support manufacturing programs from clinical through commercial.

  5. Curia Capacity Update April 2025: Fill/Finish 4/25/2025

    Discover how proven sterile fill-finish expertise, high-potency capabilities, and customizable cleanrooms can support your product from development to commercialization.

  6. IDT Biologika Capacity Update April 2025: Fill/Finish 4/25/2025

    Watch as Senior Key Account Manager, Dr. Jürgen Lübbehusen highlights IDT Biologika´s overall fill-finish capabilities and capacities, with a focus on our ability to help meet your complex needs.

  7. FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Fill/Finish 4/25/2025

    Executive Director of Technology and Business Development for Drug Product and Finished Goods, Henrik Herrmann, shares an update on the current and future state of FDB’s capabilities.

  8. Argonaut Capacity Update April 2025: Fill/Finish 4/25/2025

    Advance your clinical and commercial programs with expert aseptic fill finish and formulation services across vials, cartridges, and syringes, all in state-of-the-art, EU Annex 1-compliant facilities.

  9. A Checklist For Mechanism-Based Potency Testing In Cell Therapy 4/25/2025

    New research concludes that potency cannot be decoupled from a product's mechanism of action because surrogate markers fail to capture functional relevance.

  10. Orion And Criceto Announce A License Agreement For APORON, An Innovative Apomorphine Spray To Treat OFF Episodes In Parkinson's Disease 4/25/2025

    Orion Corporation (“Orion”) and Criceto IKM B.V. (“Criceto”) today announced the signing of an exclusive license agreement for the development and commercialization of APORON, a novel apomorphine oromucosal spray for the treatment of OFF episodes in patients with Parkinson’s disease. APORON is currently in Phase 3 development by Criceto.